Krystal Biotech (KRYS)
NASDAQ:KRYS
Want to see KRYS full AI Analyst Report?
KRYS Stock Chart & Stats
$274.21
-$3.73(-2.33%)
At close: 4:00 PM EST
$274.21
-$3.73(-2.33%)
Day’s Range― - ―
52-Week Range$122.80 - $303.00
Previous CloseN/A
Volume44.50K
Average Volume (3M)269.54K
Market Cap
$8.52B
Enterprise Value$8.02B
Total Cash (Recent Filing)$823.40M
Total Debt (Recent Filing)$1.80M
Price to Earnings (P/E)33.8
Beta0.71
Next Earnings
Aug 10, 2026EPS Estimate
1.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.75
Shares Outstanding29,479,755
10 Day Avg. Volume260,085
30 Day Avg. Volume269,539
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)5.85
Price to Sales (P/S)18.34
P/FCF Ratio37.77
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue19.22
Enterprise Value/Gross Profit20.71
Enterprise Value/Ebitda43.25
Forecast
1Y Price Target
$323.11Price Target Upside17.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)7.54
Revenue Forecast (FY)$520.17M
Bulls Say, Bears Say
Bulls Say
International ExpansionAnalyst expects international launches of Vyjuvek and an expanding distributor network to materially increase revenue as payer agreements progress and patient access widens.
KB801 Dosing And Competitive PositioningAnalyst highlights KB801 as a major catalyst because a simpler, home-friendly dosing regimen could attract patients from competitors with more burdensome administration and drive market share gains.
Platform De‑risking And Regulatory PathwayAnalyst points to RMAT designation and advancement of the HSV-1 therapeutic platform into registrational-stage studies as factors that reduce regulatory risk and could accelerate approval timelines across indications.
Bears Say
Ocular Dosing Tolerability And Trial RiskAnalyst notes increased dosing frequency in eye programs raises tolerability concerns and may necessitate re-enrollment, creating risk of slower trial progression and potential delays.
Pricing And Reimbursement UncertaintyAnalyst warns that unresolved pricing negotiations in key European markets could delay revenue recognition and pressure realized pricing if agreements require accruals or resets.
Valuation And Pipeline De‑riskingAnalyst recommends waiting for additional pipeline de‑risking, citing that current valuation appears to assume broad clinical success and limits upside if programs encounter setbacks.
Krystal Biotech News
KRYS FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $122.80 and its highest was $303.00 in the past 12 months.
What is Krystal Biotech’s market cap?
Krystal Biotech’s market cap is $8.52B.
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is Aug 10, 2026 which is in 95 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on May 04, 2026. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.34.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is 1.79.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 29,479,755 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of $1.83 in its last earnings report, beating expectations of $1.49. Following the earnings report the stock price went up 7.86%.
Which hedge fund is a major shareholder of Krystal Biotech?
Currently, no hedge funds are holding shares in KRYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Krystal Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$323.11 (17.83% Upside)
$323.11 (17.83% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 18.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $31.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.66%
12-Months-Change
Fundamentals
Return on Equity
19.25%
Trailing 12-Months
Asset Growth
30.02%
Trailing 12-Months
Company Description
Krystal Biotech
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
KRYS Company Deck
KRYS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum, robust profitability, a growing international launch and a busy clinical pipeline with multiple near-term readouts and regulatory designations — balanced by operational challenges including insurance switchovers, start-stop treatment dynamics, rising G&A, certain program-specific regulatory/timing requirements, and ongoing European pricing negotiations. Overall the positives (revenue growth, high gross margin, strong cash position, multiple upcoming data readouts and regulatory designations) materially outweigh the operational and timing headwinds described.View all KRYS earnings summariesKRYS Stock 12 Month Forecast
Average Price Target
$323.11
▲(17.83% Upside)
Technical Analysis
Ownership Overview
11.32% Insiders
30.35% Mutual Funds
1.25% Other Institutional Investors
31.91% Public Companies and
Individual Investors